Cytori to Present at the 9th Annual LD Micro Main Event Conference on December 6th, 2016

SAN DIEGO, Dec. 05, 2016 -- Cytori Therapeutics, Inc. (NASDAQ:CYTX), a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions, announced today that management will present at the 9^th Annual LD Micro Main Event Conference. The Presentation will take place on Tuesday, December 6, 2016 at 12:00PM PST, in Track 4 at the Luxe Sunset Hotel in Los Angeles, CA.

Management will be available on Tuesday, December 6 and Wednesday, December 7, 2016 for one-on-one meetings. To schedule a meeting or for more information, please contact [email protected].

About LD Micro

The LD Micro Main Event is the largest independent conference for small/microcap companies and will feature 240 presenting names. LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event). In 2015, LDM launched the first pure microcap index (LDMi) to exclusively provide intraday information on the entire sector.

About Cytori Therapeutics

Cytori Therapeutics is a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. For more information: visit www.cytori.com.

Cytori Therapeutics, Inc.

Tiago Girao, +1 (858) 458.0900

[email protected]